Lung Cancer News and Research

Latest Lung Cancer News and Research

Varian highlights numerous lung cancer treatment systems at ASTRO meeting

Varian Medical Systems highlighted the company's technologies for the non-invasive treatment of lung cancer at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston this week.

1 Nov 2012

Biomarker discovery offers hope for lung cancer blood test

Blood levels of a variant form of the nuclear matrix protein Ciz1 are significantly higher in individuals with early- and late-stage lung cancer than in lung cancer-free individuals, researchers report.

31 Oct 2012

Radiation therapy protocol deviations associated with increased risk of treatment failure and overall mortality

Radiation therapy protocol deviations in clinical trials are associated with increased risk of treatment failure and overall mortality, according to a study entitled, “Radiotherapy Protocol Deviations are Associated with Inferior Clinical Outcomes: A Meta-analysis of Cooperative Group Clinical Trials” to be presented today at the 54th annual meeting of the American Society for Radiation Oncology (ASTRO) in Boston, MA.

30 Oct 2012

Array BioPharma first quarter 2013 revenue decreases to $15.8 million

Array BioPharma Inc. today reported results for the first quarter of its fiscal year ending June 30, 2013.

30 Oct 2012

Positive results from Celldex’s CDX-1401 Phase 1 study on solid tumors

Celldex Therapeutics, Inc. today announced positive results demonstrating promising clinical effects in a Phase 1 study of CDX-1401 in solid tumors in combination with the toll-like receptor (TLR) agonists resiquimod and/or Poly ICLC.

30 Oct 2012

Metabolic syndrome increases erectile dysfunction risk

The metabolic syndrome is an independent risk factor for the development of erectile dysfunction in Chinese men, especially among those who are middle-aged, show study findings.

29 Oct 2012

Botanical treatment holds hope for triple-negative breast cancer

A unique formula made from medicinal mushrooms, traditional Chinese herbs and other natural ingredients inhibits aggressive, human triple-negative breast cancer and breast-to-lung metastasis in mice. This is the third peer-reviewed study to demonstrate the botanical formula's anticancer effects.

29 Oct 2012

Cellectis announces successful programming of immune system cells to kill cancer cells

Cellectis, the genome engineering specialist, has announced successfully programming cells from the immune system (T cells) to kill cancer cells. This technological breakthrough was revealed for the first time ever on Saturday, October 27th at the congress of the ESGCT (European Society of Gene & Cell Therapy) in Versailles, outside Paris.

29 Oct 2012

Female smokers who stop before middle age on average gain ten extra years of life

The largest-ever study of the hazards of smoking and benefits of stopping for women in the UK has shown that female smokers lose at least ten years of lifespan, but that stopping before the age of 40, and preferably well before the age of 40, avoids more than 90% of the increased risk of dying caused by continuing to smoke, while stopping before the age of 30 avoids over 97% of it.

29 Oct 2012

GTx to continue enobosarm Phase III trials for muscle wasting in patients with NSCLC

GTx, Inc. today announced that a per protocol interim safety review on Friday, October 26, 2012, by an independent Data Safety Monitoring Board (DSMB) recommended that GTx continue clinical development as planned with its two pivotal Phase III trials of enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer.

29 Oct 2012

Research roundup: Patients' unrealistic expectations for chemo; Neighborhood may affect CPR rates; Rate hike reviews working

"To make informed decisions about whether to receive chemotherapy, patients with advanced lung or colorectal cancer need a realistic understanding of its likely benefits," the authors write. Researchers conducted comprehensive reviews of records.

29 Oct 2012

Combined antimicrobial and light therapy effective for treating foot ulcers

Results from a phase II study show that antimicrobial photodynamic therapy is significantly more effective than placebo for treating patients with chronic leg ulcers.

26 Oct 2012

Diabetes drug could treat illicit drug addiction

Researchers have found that a drug currently used to treat Type 2 diabetes could treat addiction to drugs such as cocaine.

26 Oct 2012

HbA1c equally useful across ethnic groups

Currently recommended clinical cutoff points for diabetes diagnosis using glycated hemoglobin should be interpreted similarly in Whites, Blacks, and Hispanics, show findings from a US study.

26 Oct 2012

Legume intake reduces heart disease risk in diabetes patients

Diabetes patients who incorporate legumes as part of a low glycemic index diet improve their glycemic control and reduce their risk for coronary heart disease, a study shows.

25 Oct 2012

Geographic variations in US diabetic foot expenditure identified

Researchers report that in the USA, Medicare spending on patients with diabetic foot disease varies significantly between different hospital referral regions.

25 Oct 2012

Four-point plan to improve palliative care discussions

In an editorial appearing in the October 25 issue of The New England Journal of Medicine, medical oncologists at Johns Hopkins and Brigham and Women's hospitals provide a four-point plan for integrating palliative care discussions throughout the treatment of patients with terminal illnesses.

25 Oct 2012

CINJ makes experts available during National Lung Cancer Awareness Month

According to the American Cancer Society, nearly 6,000 new cases of lung cancer are expected to be diagnosed in New Jersey this year, and 4,200 people will die from the disease.

25 Oct 2012

FDA accepts ARIAD’s ponatinib NDA for filing

ARIAD Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for accelerated review of ARIAD's investigational BCR-ABL inhibitor, ponatinib, in patients with resistant or intolerant chronic myeloid leukemia (CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

25 Oct 2012

Metabolic pathway for insulin effects of sleep identified

Sleep deprivation reduces insulin sensitivity in human fat cells, which could, over time, lead to metabolic disorders such as diabetes, researchers report.

23 Oct 2012